Literature DB >> 7125626

In vitro synergistic activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against Mycobacterium avium-intracellulare complex.

B L Zimmer, D R DeYoung, G D Roberts.   

Abstract

Strains of Mycobacterium avium-intracellulare complex often exhibit in vitro resistance to common antimycobacterial agents. Combinations of etambutol, isoniazid, kanamycin, rifampin, and streptomycin were tested to determine if synergism occurred. Ninety-six percent of the strains were susceptible to a combination of ethambutol and rifampin at concentrations attainable clinically. Other combinations of antimycobacterial agents inhibited 4 to 82% of the isolates tested.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7125626      PMCID: PMC183690          DOI: 10.1128/AAC.22.1.148

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  [Sensitivities of atypical mycobacteria to various drugs. III. Sensitivities of M. intracellulare to antituberculous drugs in triple combinations (author's transl)].

Authors:  F Kuze; S Takeda; N Maekawa
Journal:  Kekkaku       Date:  1977-07

2.  Comparison of techniques for measurement of in vitro antibiotic synergism.

Authors:  C W Norden; H Wentzel; E Keleti
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

3.  Antimicrobial synergism--an elusive concept.

Authors:  R C Moellering
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

4.  Rifampin: in vitro effect on atypical mycobacteria.

Authors:  T K Rynearson; J S Shronts; E Wolinsky
Journal:  Am Rev Respir Dis       Date:  1971-08

5.  Long-term results of medical treatment in Mycobacterium intracellulare infection.

Authors:  A K Dutt; W W Stead
Journal:  Am J Med       Date:  1979-09       Impact factor: 4.965

6.  Influence of the medium on the in vitro susceptibility of Mycobacterium tuberculosis to ethambutol.

Authors:  P R Gangadharam; E R Gonzales
Journal:  Am Rev Respir Dis       Date:  1970-10

7.  The relative drug susceptibility of opaque colonial forms of Mycobacterium intracellulare-avium: does it affect therapeutic results?

Authors:  T Moulding
Journal:  Am Rev Respir Dis       Date:  1978-06

8.  Identification of clinical isolates of mycobacteria with gas-liquid chromatography alone.

Authors:  P A Tisdall; G D Roberts; J P Anhalt
Journal:  J Clin Microbiol       Date:  1979-10       Impact factor: 5.948

9.  Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases.

Authors:  D Y Rosenzweig
Journal:  Chest       Date:  1979-02       Impact factor: 9.410

10.  New approach for the evaluation of antimycobacterial drug combinations in vitro (the laboratory model man).

Authors:  K D Stottmeier; C L Woodley; G P Kubica
Journal:  Appl Microbiol       Date:  1969-09
  10 in total
  23 in total

Review 1.  Treatment of pulmonary disease caused by opportunist mycobacteria.

Authors:  J Banks
Journal:  Thorax       Date:  1989-06       Impact factor: 9.139

Review 2.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

3.  In vivo activities of newer rifamycin analogs against Mycobacterium avium infection.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

4.  Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice.

Authors:  C B Inderlied; P T Kolonoski; M Wu; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

5.  Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium.

Authors:  S E Hoffner; S B Svenson; G Källenius
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

6.  Antimicrobial synergism against Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndrome.

Authors:  D M Yajko; J Kirihara; C Sanders; P Nassos; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

7.  Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

8.  Effects of antimicrobial agents on survival of Mycobacterium avium complex inside alveolar macrophages obtained from patients with human immunodeficiency virus infection.

Authors:  D M Yajko; P S Nassos; C A Sanders; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

9.  In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium.

Authors:  D M Yajko; C A Sanders; J J Madej; V L Cawthon; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations.

Authors:  S E Hoffner; U Hjelm; G Källenius
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.